Satellos Bioscience Inc., a clinical-stage biotechnology company dedicated to developing transformative therapies for degenerative muscle diseases, announced today that it will present two scientific posters at the upcoming 30th Annual Congress of the World Muscle Society (WMS), scheduled to take place October 7–11, 2025, in Vienna, Austria.
The presentations will highlight new analyses from the Phase 1b clinical study of SAT-3247, Satellos’ lead investigational therapy for Duchenne muscular dystrophy (DMD), a severe and progressive genetic disorder that leads to muscle degeneration and premature loss of ambulation.
Advancing a Novel Approach to Duchenne
DMD affects approximately one in every 3,500 to 5,000 live male births worldwide and remains one of the most serious childhood-onset neuromuscular diseases. While recent therapeutic advances have brought hope to certain subsets of patients, there remains a significant unmet need for broadly effective treatments that can address the underlying pathology of muscle degeneration.
Satellos is developing SAT-3247 as a first-in-class, orally administered small molecule designed to correct deficits in muscle repair and regeneration. The therapy aims to restore normal muscle stem cell function, thereby enabling continuous muscle repair — a biological process that is impaired in patients with Duchenne. Unlike many mutation-specific gene-targeted therapies, SAT-3247 has the potential to address the disease regardless of the underlying genetic mutation.
“Our work is driven by a commitment to target the root biological defect in Duchenne: the inability of muscle stem cells to effectively repair and regenerate damaged muscle tissue,” said Frank Gleeson, co-founder and Chief Executive Officer of Satellos. “By developing SAT-3247, we hope to create a treatment that can be accessible to the broader Duchenne population. Presenting our Phase 1b data at WMS is an important step in sharing our progress with the global scientific and medical community.”
Late-Breaking Poster Presentation
One of Satellos’ highlights at WMS will be a late-breaking poster featuring results from its first-in-human study of SAT-3247:
- Abstract Title: A phase 1a/b open-label study of SAT-3247 in healthy volunteers and adult patients with Duchenne muscular dystrophy (Poster #712LBP)
- Presenter: Wildon Farwell, MD, MPH, Chief Medical Officer, Satellos
- Session: Poster Session 4
- Date & Time: Friday, October 10, 3:45–4:45 p.m.
This poster will share data on the safety, tolerability, and pharmacokinetics of SAT-3247, as well as early signals related to its potential clinical activity.
Clinical Progress Update Poster
Satellos will also present a second poster providing an update on the broader development of SAT-3247:
- Abstract Title: Clinical progress update for SAT-3247, a first-of-its-kind, orally administered small molecule drug to address deficits in muscle repair and regeneration in Duchenne (Poster #411P)
- Presenter: Ryan Mitchell, PhD, Senior Vice President, Medical & Scientific Affairs, Satellos
- Session: Poster Session 1
- Date & Time: Wednesday, October 8, 2:30–3:30 p.m.
This presentation will outline the company’s clinical strategy and next steps as it advances SAT-3247 through development, including its plans for future trials in pediatric patients.
Looking Ahead
The World Muscle Society Congress is one of the most influential scientific meetings in the neuromuscular disease community, bringing together leading researchers, clinicians, and industry stakeholders. By presenting both late-breaking clinical data and a broader development update, Satellos aims to engage with the international community on the potential of SAT-3247 to redefine treatment approaches for Duchenne.
“Sharing our data at WMS underscores the momentum we are building as we move forward with SAT-3247,” added Gleeson. “We believe this medicine has the potential to make a meaningful difference for patients and families affected by Duchenne muscular dystrophy, and we look forward to continued dialogue with the scientific and medical community.
Full details from the poster presentations will follow in a future press release and will be available on the Events and Presentations page of the Satellos website.
For more information on the 30th Annual Congress of the World Muscle Society, visit www.wms2025.com.
ABOUT SAT-3247
SAT-3247 is a proprietary, oral, small molecule drug being developed by Satellos as a novel treatment to regenerate skeletal muscle that is lost in Duchenne muscular dystrophy and other degenerative or injury conditions. Satellos is advancing SAT-3247 as a potential treatment for DMD, independent of dystrophin and regardless of exon mutation status.
ABOUT SATELLOS BIOSCIENCE INC.
Satellos is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, Satellos has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that Satellos has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration.
By restoring this missing dystrophin signal in DMD, SAT-3247 enables muscle stem cells to divide properly and more efficiently, promoting natural muscle repair and regeneration. SAT-3247 is currently in clinical development as a potential disease-modifying treatment initially for DMD. Satellos also is leveraging its proprietary discovery platform MyoReGenX™ to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. For more information, visit www.satellos.com.
